Simon Harnest

Simon Harnest joined Prolynx as Chief Financial Officer in July 2026, leading the company's financial strategy as it advances a portfolio of ultra-long-acting medicines for obesity and metabolic diseases toward clinical development. Harnest brings deep experience helping life sciences companies scale through key financing and growth milestones, including three Nasdaq IPOs and more than $1 billion in capital raised. His experience spans capital strategy, investor engagement, corporate development, and public-market execution.

Harnest brings more than 15 years of experience in biotechnology finance, capital markets and corporate strategy. Before joining Prolynx, he served as Chief Financial Officer of Totus Medicines and Chief Investment Officer of Metagenomi, where he led private financings and the company's IPO process. Previously, at Cellectis, he directed U.S. capital markets strategy, the company's U.S. IPO and follow-on financings, as well as the spinout and IPO of Calyxt. Earlier in his career, Simon advised private and publicly traded life sciences companies at The Trout Group and Trout Capital.

Career History

• Chief Financial Officer, Prolynx (2026–present)
• Chief Financial Officer, Totus Medicines (2025–2026)
• Chief Investment Officer, Metagenomi (NASDAQ: MGX)
• Director of U.S. Capital Markets Strategy, Cellectis (NASDAQ: CLLS)
• Vice President, The Trout Group / Trout Capital

Simon holds an MSc in Public Health from the London School of Economics and Political Science and a BSc in Economics from the University of Westminster.

What Simon Harnest could bring to CFO at Prolynx: Harnest's demonstrated track record scaling biotech companies through critical financing milestones and public markets execution positions him to navigate Prolynx's advancement toward IND-enabling studies and eventual clinical development. His experience managing capital strategy and investor relations across three successful IPOs, combined with expertise in corporate development at growth-stage companies, aligns with Prolynx's need to optimize financial operations and secure funding for its ultra-long-acting obesity and metabolic disease pipeline.